10-Q · May 20, 2026
Lifeward Ltd. reported disappointing Q1 2026 results, with revenue of $3.923 million falling 22% year-over-year and significantly underperforming expectations of $5.84 million. The company's EPS loss of $6.70 was much…
Earnings analysis · 10-Q
LFWD earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Lifeward delivered a strong sequential revenue recovery, with Q2 revenue of $6.623 million up 16% year over year and operating losses narrowing materially. However, gross margin declined year over year, net loss…
Read full summary
Lifeward delivered a strong sequential revenue recovery, with Q2 revenue of $6.623 million up 16% year over year and operating losses narrowing materially. However, gross margin declined year over year, net loss increased to $11.519 million because of $7.357 million in financial expense, and operating cash burn remained high at $9.680 million for the first half. The July financing improves near-term liquidity, but the company still reports substantial doubt about its ability to continue as a going concern and expects additional financing until profitability or positive cash flow is achieved.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-4.12
- Segment
- AlterG: Q2 revenue increased by approximately $0.8 million year over year, driven primarily by higher U.S. unit shipments, service revenue and average selling prices.
- Segment
- ReWalk: Revenue increased year over year, primarily due to stronger European sales and increased CMS revenue; exact segment revenue was not disclosed.
- Segment
- ReStore and MyoCycle: Included in consolidated revenue, but standalone revenue was not disclosed.
What stood out
-
Revenue Rebounded Sharply
Q2 revenue was $6.623 million, up $0.899 million, or 16%, from $5.724 million in Q2 2025 and approximately 66% from $4 million in Q1 2026. Management called it the strongest quarterly revenue performance since Q4 2024.
-
Sequential Margin Recovery
Gross margin was 40.9%, down from 43.9% year over year but up from 34.2% in Q1 2026. Gross profit increased to $2.709 million from $2.511 million in Q2 2025.
-
Operating Loss Improved
Operating loss narrowed to $4.152 million from $6.563 million in Q2 2025, improving operating margin to negative 62.7% from negative 114.7%; the prior-year period included a $2.783 million goodwill impairment charge.
-
EPS Loss Narrowed
Diluted EPS improved to negative $4.12 from negative $7.01 year over year and negative $6.70 in Q1 2026, although the one-for-twelve reverse split effective February 24, 2026 affects share-count comparability.
-
Liquidity Enhanced by Financing
Cash and cash equivalents were $9.4 million at June 30, 2026. A July 6 financing raised approximately $5.6 million, including $4.1 million received during Q2 and $1.5 million received in July, with an additional approximately $5.6 million available subject to specified milestones.
-
Distribution Expansion Continues
Management expects future growth to be driven by ReWalk reimbursement and channel partnerships, while an August 2026 Ottobock Care pilot provides access to more than 50 U.S. patient clinics.
What to watch
-
Going-Concern Financing Risk
The filing states there is substantial doubt about going-concern status. Cash was $9.4 million at June 30, 2026, accumulated deficit was $307.1 million, and management expects future net losses and continued financing needs until profitability or positive operating cash flow is achieved.
-
Persistent Cash Burn
Operating cash use increased 3% to $9.680 million in the first six months of 2026 from $9.429 million in the prior-year period. The filing does not disclose a six-month capital-expenditure figure, so free cash flow cannot be calculated from the provided data.
-
Margin Pressure Persists
Gross margin declined to 40.9% from 43.9% year over year, with management citing adverse foreign-exchange movements, higher tariffs and revenue-sharing expense related to the Oramed transaction. Six-month gross margin fell to 38.4% from 43.1%.
-
Financing Costs Increased Loss
Net loss widened to $11.519 million from $6.562 million year over year despite the operating-loss improvement, primarily because net financial expense rose to $7.357 million from net financial income of $0.001 million, reflecting fair-value changes in warrant and derivative liabilities and convertible-note interest.
Management's outlook
No numeric revenue or EPS guidance was provided. Management expects future growth to be driven by ReWalk reimbursement and channel expansion and expects increased AlterG shipments over time; it also expects gross profit and gross margin to improve as volumes increase and fixed-cost absorption and efficiency initiatives take effect.
Earlier filings 4
10-K · March 18, 2026
Lifeward describes a strategic shift from a pure exoskeleton company toward a broader biomedical platform (acquisitions, distribution deals and IP buys) but reported declining revenue and large losses in 2025.…
10-Q · May 15, 2025
Lifeward reported Q1 revenue of $5,034,000 and a GAAP net loss of $4,834,000 (loss per share $0.46). Gross profit improved to $2,122,000 (42.2% margin) while operating loss narrowed to $4,853,000. Cash and cash…
10-K · March 7, 2025
Lifeward’s 10-K (period ended 2024-12-31) describes a medical-device company repositioning around its ReWalk exoskeletons, the 2023 AlterG acquisition and reimbursement wins while continuing to generate operating losses…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.